Nijmegen, The Netherlands (May 10th, 2022) – Thirona, expert in AI-powered quantitive analysis of thoracic CT-scans, is pleased to announce the appointment of prof. Harm Tiddens as her Chief Medical Officer. The appointment reflects Thirona's mission of bringing science to the clinics faster, to benefit all people.

We are very glad to announce that prof. Tiddens has joined Thirona, as Thirona's part time Chief Medical Officer, next to his position as full professor in pediatric pulmonology at the department of Pediatric Respiratory Medicine and Allergology at the Erasmus Medical Center-Sophia Children's Hospital and his position as honorary professor at the department of radiology and nuclear medicine at the Erasmus Medical Center. Being the founder and director of the Erasmus MC Lung Analysis laboratory, he is an internationally respected expert in the field of development and validation of imaging techniques and imaging outcome measures for chronic lung diseases such as cystic fibrosis, asthma, bronchiectasis, bronchopulmonary dysplasia, and primary ciliary dyskinesia.

"His expertise and determination in bringing image analysis methods to clinical care will bring significant value to the company", says Eva van Rikxoort, CEO and founder of Thirona. "We have been collaborating closely with prof. Tiddens and Erasmus Medical Center for many years. As Thirona focuses on treatment of both common and rare pulmonary diseases, rather than only on screening of the most common types, we are happy to have prof. Tiddens bringing decades of valuable experience to the team."
'I am looking forward to working closely with the R&D and commercial teams, and to engage in developing innovative image analysis tools. The focal point, in my role as CMO, will be at the clinical benefits and at articulating 'the voice of the patient', making sure that our technology brings a true impact to patients suffering from a wide array of lung and respiratory diseases', says Harm Tiddens.


About Thirona
Thirona is an innovative company specializing in artificial intelligence for medical image analysis that allow for precise quantification of disease symptoms and contribute to personalized patient treatment. Thirona partners with research institutions and medical companies in their innovation trajectories aimed to enable breakthroughs in treatment development and clinical care. Founded in 2014 by female scientist Eva van Rikxoort, the company develops highly innovative deep learning solutions for lung and retinal image analysis. Rooted in science and providing reliable and user-friendly solutions, it bridges the gap between academic ideas and clinical use. Since inception in 2014, Thirona has become an important player in the medical imaging field.

RetCAD™, one of Thirona's brands, is a MDR class IIa certified software using artificial intelligence that analyses color fundus images for the presence of eye diseases. It assists eye care providers in early diagnosis and grading of the vision threatening diseases. RetCAD™ uses state-of-the-art deep learning and computer vision technology, utilizing large amounts of human-specialist graded images, to provide quantified clinical outcome measures. Description to the photo (attached): Prof. Harm Tiddens, MD, PhD, Chief Medical Officer at Thirona

More People on the Move